AbCellera aims to speed up how new antibody medicines are found and made by pairing its lab platform with AI, and it’s starting to push more of its own drug candidates forward instead of relying only on partners. The upside is faster progress and new partner deals, but big spending, trial setbacks, and a tougher biotech funding climate could delay results.Read more
AbCellera is trying to shift from being a behind-the-scenes antibody discovery partner into a company that runs its own early human trials, starting with two new drug candidates. The big question is whether its new in-house manufacturing and fresh partnerships can turn promising lab work into real medicines before cash burn and tough competition catch up.Read more
AbCellera is betting big on using advanced software and automation to speed up antibody drug discovery, but its future depends on clinical results and royalty payments that can swing wildly. Competition from other platforms and shifting rules and payment pressures in healthcare could make it hard for those investments to turn into steady profits.Read more
No trending discussion available.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
